Kinetics of valproic acid glucuronidation: Evidence for in vivo autoactivation

Drug Metabolism and Disposition

Volumn 35, Issue 8, 2007, Pages 1380-1386

  Wong, Harvey ^a   Tong, Vincent ^b   Riggs, K Wayne ^c   Rurak, Dan W ^d   Abbott, Frank S ^c   Kumar, Sanjeev ^b  

^a GENENTECH INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID GLUCURONIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG GLUCURONIDATION; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME MECHANISM; ENZYME SUBSTRATE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN; PLASMA; PRIORITY JOURNAL; SHEEP; URINARY EXCRETION;

ANIMALS; CATALYSIS; ENZYME ACTIVATION; FEMALE; KINETICS; MICROSOMES, LIVER; SHEEP; VALPROIC ACID;

OVIS ARIES;

EID: 34547171195     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015719     Document Type: Article

References (18)

1. Booth CL, Pollack GM, and Brouwer KLR (1996) Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 23:771-780.
2. Court MH, Duan SX, Von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
3. Davis R, Peters DH, and McTarvish D (1994) Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372.
4. Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
5. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel Dekker, New York.
6. Granneman GR, Marriott TB, Wang SI, Sennello LT, Hagen NS, and Sonders RC (1984) Aspects of dose-dependent metabolism of valproic acid, in Metabolism of Antiepileptic Drugs (Levy RH, Pitlick WH, Eichelbaum M, and Meijer J eds) pp 97-104, Raven Press, New York.
7. Houston JB (1986) Drug metabolite kinetics, in Pharmacokinetics: Theory and Methodology (Rowland M and Tucker GT eds) pp 131-162, Pergamon Press, Oxford.
8. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
9. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ, and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
10. Kumar S, Riggs KW, and Rurak DW (1999) Role of the liver and gut in systemic diphenhydramine clearance in adult nonpregnant sheep. Drug Metab Dispos 27:297-302.
11. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
12. Tong V, Teng XW, Karagiozov S, Chang TK, and Abbott FS (2005) Valproic acid glucuronidation is associated with increases in 15-F2t-isoprostane in rats. Free Radic Biol Med 38:1471-1483.
13. Ueng Y-F, Kuwabara T, Chun Y-J and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
14. Wagner JG (1993) Pharmacokinetics for the Pharmaceutical Scientist, Technomic Publishing, Lancaster, PA.
15. Wilkinson GR and Shand DG (1975) A physiologic approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
16. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65.
17. Wong H, Rurak DW, Kumar S, Kwan E, Abbott FS, and Riggs KW (2001) Dose dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. Drug Metab Dispos 29:664-675.
18. Yu D, Gordon JD, Zheng J, Panesar SK, Riggs KW, Rurak DW, and Abbott FS (1995) Determination of valproic acid and its metabolites using gas chromatography with mass-selective detection: Application to serum and urine samples from sheep. J Chromatogr B Biomed Appl 666:269-281.